A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent Glioblastoma

Inclusion Criteria:

- Histological confirmed diagnosis of relapsed intracranial GB

- Progressive Disease (PD) following standard chemoradiation

- Prior surgical resection allowed

- Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1

- Adequate hematologic, hepatic and renal function

- Discontinued all prior cancer treatments for cancer & recovered from the acute
effects of therapy

- Tumor specimen must be available for a central pathology review and prognostic and
predictive biomarker evaluation

Exclusion Criteria:

- Moderate or severe heart disease based on New York Heart Association (NYHA) criteria

- Prior nitrosurea therapy (including lomustine or Gliadel)

- Prior bevacizumab as 1st line treatment for GB (if treatment was concluded 12 months
prior to enrollment, the patient may be eligible to participate in the trial)

- Current acute or chronic myelogenous leukemia

- Second primary malignancy that may affect the interpretation of results

- Serious concomitant systemic disorder